ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
January 30 2012 - 11:00AM
ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that
develops targeted anticancer therapeutics using its antibody
expertise, today announced the addition of Kristine Peterson and
Dean Mitchell to the Company's Board of Directors.
"Both Kris and Dean have more than 25 years of experience in the
healthcare industry, including extensive expertise in product
development and commercialization," commented Stephen McCluski,
Chairman of the Board. "As ImmunoGen's product pipeline continues
to advance and expand, this expertise has become increasingly
important in shaping corporate direction and priorities."
Ms. Peterson is CEO of Valeritas, Inc., and also a director on
its board. She previously was Company Group Chairman, Biotech
Business, at Johnson & Johnson, where she was responsible for
research, development, manufacturing, and commercialization of
oncology, immunology, and other biotechnology therapeutics for the
company. Prior to joining J&J in 2004 as Executive VP,
Pharmaceutical Group Strategic Marketing, Ms. Peterson had a
twenty-year career with Bristol-Myers Squibb, rising through the
organization to become Senior VP, Global Marketing before taking
Senior VP and President roles at Biovail Corporation in 2003. Ms.
Peterson is active in the Biotechnology Industry Organization (BIO)
and also serves on the board of Amarin Corporation.
Mr. Mitchell is President and CEO of Lux Biosciences, Inc., and
also a director on its board. He previously was President and CEO
of Alpharma, Inc. and, before that, of Guilford Pharmaceuticals.
Prior to joining Guilford in 2004, Mr. Mitchell held senior-level
positions at Bristol-Myers Squibb, including President,
International Pharmaceuticals and President, North America Primary
Care. Prior to joining Bristol-Myers Squibb in 2001, Mr. Mitchell
had a fourteen-year career with GlaxoSmithKline, Inc., becoming
Senior Vice President, Clinical Development and Product Strategy in
2000. Mr. Mitchell is also a director of Intrexon Corporation and
of Ista Pharmaceuticals.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's Targeted Antibody Payload (TAP) technology uses
monoclonal antibodies to deliver one of ImmunoGen's proprietary
cancer-cell killing agents specifically to tumor cells. There are
now numerous TAP compounds in clinical development with a wealth of
clinical data reported. ImmunoGen's collaborative partners include
Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Lilly, Novartis,
Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP
technology, trastuzumab emtansine (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech, a member of the
Roche Group. More information about ImmunoGen can be found at
www.immunogen.com.
CONTACT: For Investors:
Carol Hausner
Executive Director, Investor Relations
and Corporate Communications
ImmunoGen, Inc.
(781) 895-0600
info@immunogen.com
For Media:
Barbara Yates
The Yates Network
(781) 258-6153
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024